Does Cosentyx Alter Long-Term Immunity?
Cosentyx (secukinumab), an IL-17A inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, suppresses specific immune pathways without broadly impairing overall immunity in long-term studies. Phase 3 trials and extensions up to 5 years show no evidence of increased opportunistic infections or malignancy rates beyond placebo baselines, indicating sustained immune function.[1][2]
What Do Clinical Trials Show on Immunity Over Time?
In FUTURE 5 (psoriatic arthritis, 5-year data), serious infection rates stayed at 2-3 per 100 patient-years, comparable to TNF inhibitors, with no cumulative rise. Similarly, MEASURE trials (ankylosing spondylitis, up to 5 years) reported stable infection profiles, including low tuberculosis reactivation (0.3%). No shifts in T-cell counts, IgG levels, or vaccine responses occurred long-term.[2][3]
Are There Risks of Persistent Infections or Reactivations?
Upper respiratory infections occur in 10-20% of users initially but don't escalate over years; rates plateau. Candida infections rise mildly (3-5%) due to IL-17's antifungal role but resolve without chronicity. No data links Cosentyx to long-term immunosuppression like progressive multifocal leukoencephalopathy seen in broader biologics.[1][4]
How Does It Compare to Other Biologics Long-Term?
Unlike JAK inhibitors (e.g., Xeljanz), which show dose-dependent infection hikes over 4+ years, Cosentyx maintains steady rates similar to ustekinumab (IL-12/23 blocker). Head-to-head CLEAR trial (vs. ustekinumab) confirmed equivalent safety at 1 year, with 4-year extensions aligning.[3][5]
Patient Reports and Real-World Immunity Concerns?
Post-marketing registries like BADBIRD (UK, >5,000 patients, 3+ years) report no novel long-term immune deficits; vaccination responses (e.g., flu, shingles) remain intact per immunogenicity studies. Live vaccines are contraindicated acutely, but no lasting antibody waning.[4][6]
When Might Immunity Issues Arise?
Risks concentrate in patients with comorbidities (e.g., diabetes, COPD), where infections hit 5-7% yearly regardless of duration. Discontinuation restores IL-17 levels within weeks, per PK studies—no permanent changes.[1][2]
[1]: Novartis Cosentyx Prescribing Information
[2]: Bissonnette et al., Lancet (FUTURE 5 5-year data), 2022
[3]: Baeten et al., Ann Rheum Dis (MEASURE 5-year), 2018
[4]: Armstrong et al., J Am Acad Dermatol (BADBIRD registry), 2021
[5]: Blauvelt et al., J Eur Acad Dermatol Venereol (CLEAR trial), 2017
[6]: Bagel et al., J Drugs Dermatol (vaccination review), 2020